Pay in 4 interest-free payments of $6.01 Learn more
Ships within 48 hours · Estimated delivery Oct 7 - Oct 12
Appetite begins returning for most people, and the temptation to overeat is strongest
More information Positive recommendations on extensions of therapeutic indications Koselugo International non-proprietary name (INN) selumetinib Marketing authorisation holder AstraZeneca AB Orphan designation This medicine was designated an orphan medicine
Cagrilintidesemaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study, The Lancet Diabetes & Endocrinology, 14 , 8, (662-677), (2026)
E.ClarkeL
US$ 24.78
US$ 27.19
US$ 20.51
US$ 23.31
US$ 20.89
US$ 22.59
US$ 23.79
